The word is out: BioConnection invests in a second production line

In April 2019 we announced our €12 million investment in a new manufacturing line, significantly increasing our annual production capacity. With the expansion, we keep up with growing customer demands and ensure future company growth.

Market needs are evolving. As a Contract Manufacturing Organization (CMO), we experience a growing demand for our services from our existing and new customers. This made us decide to invest in expansion of our current production capacity with a second production line.

The new production line will have a fully automated fill and finish line, coupled to a fully automated freeze-dryer. The result is a significant increase in batch size, leading to an increase in our total annual production capacity. The new line can handle up to 160 batches per year and around 12 million vials per year.

Currently, our facility is inspected and certified by the EMA and US-FDA. It is of great importance to us and our customers to also have our new production line validated by these quality guidelines. Therefore, the new production line will be built taking into account all requirements to obtain EMA and US-FDA certification.

Here you can read the official press release about the €12 million investment, including a statement by Alexander Willemse, CEO of BioConnection.